Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin.

International journal of clinical pharmacology and therapeutics - 1 Apr 2003

Burian M, Freudenstein J, Tegtmeier M, Naser-Hijazi B, Henneicke-von Zepelin H H, Legrum W

Abstract excerpt

OBJECTIVE: Coumarin, used in the treatment of chronic venous diseases, is mainly metabolized to non-toxic 7-hydroxy-coumarin by CYP2A6. At least, 3 variant alleles, CYP2A6*2, CYP2A6*3 and CYP2A6*4A, have been shown to encode catalytically defective proteins. Sporadic elevation of liver enzymes ha...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Chemical and Drug Induced Liver Injury
Share to Coumarins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2A6

Share to Double-Blind Method

Share to Drug Combinations

Share to Liver Diseases

Share to Liver Function Tests

Source

Identifiers

PMID: 12708602
DOI: 10.5414/cpp41141

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12708602-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin.PMID 12708602Read ↗

The CYP2A subfamily: function, expression and genetic polymorphism.Semantic proximity Read ↗

Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.Semantic proximity Read ↗

CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.Semantic proximity Read ↗

Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).Semantic proximity Read ↗

A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.Semantic proximity Read ↗

CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking.Semantic proximity Read ↗

CYP2A6 genetic variation and potential consequences.Semantic proximity Read ↗

Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.Semantic proximity Read ↗

3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression.Semantic proximity Read ↗

CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function.Semantic proximity Read ↗

Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.Semantic proximity Read ↗

In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.